MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Diagnostic Accuracy of Parkinson’s disease: Where Do We Stand?

    S. Virameteekul (London, United Kingdom)

    Objective: To provide an up-to-date assessment of diagnostic accuracy parameters at early and late stages of the diagnosis in clinical practice and MDS Diagnostic Criteria…
  • 2022 International Congress

    A Report from Japan on Initial Experiences with Adaptive Deep Brain Stimulation Therapy for Patients with Advanced Parkinson’s Disease

    N. Tani, S. Oshino, K. Hosomi, H. Khoo, Y. Fujita, T. Emura, S. Miura, Y. Kimotto, T. Matsuhashi, X. He, A. Reza, T. Yanagisawa, H. Kishima (Suita, Japan)

    Objective: Here we present our initial experience with deep brain stimulation therapy (DBS) for Parkinson's disease (PD) using the closed-loop system. Background: Although DBS is…
  • 2022 International Congress

    Remote identification of early, sensor-based markers of Parkinson’s Disease using participants’ smartphones: The Parkinson Progression Marker Initiative Digital sub-study

    W. Popp, K. Taylor, T. Perumal, C. Tanner, A. Siderowf, L. Chahine, E. Brown, T. Simuni, T. Foroud, T. Kustermann, G. Pagano, H. Svoboda, M. Lindemann, K. Marek (Basel, Switzerland)

    Objective: To summarize the design of the Parkinson’s Progression Markers Initiative (PPMI) Digital sub-study. The study objective is to identify the earliest signs and symptoms…
  • 2022 International Congress

    Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial

    A. Bamford, S. Neumann, J. Taylor, G. Young, S. Emmett, W. Hollingworth, A. Whone, D. Steeds, C. Metcalfe, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

    Objective: This abstract provides an overview of the progress of the CHIEF-PD trial. Background: Falls are a common and debilitating consequence of Parkinson’s disease (PD).…
  • 2022 International Congress

    A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features

    C. Brücke, M. Zech, T. Outeiro, E. Gelpi, A. Zimprich (VIenna, Austria)

    Objective: To offer clinical, genetic and neuropathological information in a novel alpha-synuclein gene (SNCA) missense variant to further our understanding of synucleinopathies. Background: Around 5–10% of…
  • 2022 International Congress

    Validating a virtual Timed Up and Go (vTUG) test in Parkinson’s Disease.

    C. Matthews, R. Roberts, E. Davies, B. Falkenburger, M. Grobe-Einsler (Wrexham, United Kingdom)

    Objective: To validate the vTUG as a means of remotely monitoring patient gait and balance in the home. Background: The current regulatory gold standard for…
  • 2022 International Congress

    Affected tongue movements in idiopathic REM sleep behavior disorder

    T. Thies, N. Geerts, D. Mücke, A. Seger, M. Barbe, M. Sommerauer (Cologne, Germany)

    Objective: In Parkinson’s disease (PD), recognition of speech deviations often follows clinical diagnosis. But what if speech is a prodromal biomarker in PD? The study…
  • 2022 International Congress

    Systematic mapping of Parkinson’s disease gene interactions

    P. Antony, J. Forster, O. Kondratyeva, S. Köglsberger, R. Krüger (Belvaux, Luxembourg)

    Objective: Here, we aim to identify functional interactions between the Parkinson’s disease-associated genes. Background: Understanding how genes interact to produce a given phenotype is a…
  • 2022 International Congress

    Molecular alterations and pathological remodeling of colonic wall in patients with Parkinson’s disease

    G. Bellini, G. Palermo, D. Frosini, L. Benvenuti, C. Pellegrini, M. Bellini, N. Bernardini, M. Fornai, R. Ceravolo (Pisa, Italy)

    Objective: To evaluate, in an integrated manner, changes in faecal microbiota composition, morpho-functional alterations of the colonic mucosal barrier and changes of inflammatory markers in…
  • 2022 International Congress

    Sleep stability, arousals and cycle structure in alfa-synucleinopathies: a comparative study between isolated REM sleep behaviour disorder (iRBD), Parkinson’s Disease (PD) and Dementia with Lewy Bodies (DLB)

    M. Magriço, P. Bugalho (Lisboa, Portugal)

    Objective: To compare sleep stability, arousals and sleep cycle structure between two sets of diagnosis: iRBD vs PD vs DLB; patients with RBD (RBD+) vs…
  • « Previous Page
  • 1
  • …
  • 222
  • 223
  • 224
  • 225
  • 226
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley